Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer

肿瘤科 癌症 内科学 紫杉醇
作者
Alan Paul Lombard,Chengfei Liu,Cameron M. Armstrong,Leandro Salati D'Abronzo,Wei Lou,Hongwu Chen,Marc Dall’Era,P. Ghosh,Christopher P. Evans,Allen C. Gao
出处
期刊:Translational Oncology [Elsevier BV]
卷期号:12 (7): 871-878 被引量:30
标识
DOI:10.1016/j.tranon.2019.04.007
摘要

Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose) polymerase (PARP) is becoming an attractive therapeutic option. The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate cancer. However, several unanswered questions regarding the use of olaparib remain: 1) How do we best stratify patients for olaparib treatment? 2) Where do we place olaparib in the treatment sequence paradigm? 3) Is there cross-resistance between olaparib and currently used therapies? Here, we tested putative cross-resistance between current therapies and olaparib in treatment-resistant castration-resistant prostate cancer models. Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. Upregulated ABCB1 mediates cross-resistance between taxanes and olaparib, which can be overcome through decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or enzalutamide. We also show that combining olaparib with enzalutamide is more effective in olaparib-sensitive cells than either single agent. Our results demonstrate that cross-resistance between olaparib and other therapies could blunt response to treatment and highlight the need to develop strategies to maximize olaparib efficacy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大佬发布了新的文献求助10
刚刚
万能图书馆的应助被FZ采纳,获得10
1秒前
AAA袁氏茶馆完成签到,获得积分10
1秒前
无花果的应助被刘白采纳,获得10
1秒前
水煮电吹风的应助被LL采纳,获得10
1秒前
裴腾骏完成签到,获得积分10
1秒前
2秒前
科研通AI6.2的应助被zo采纳,获得10
3秒前
3秒前
浮云客发布了新的文献求助10
7秒前
7秒前
ChoHing发布了新的文献求助10
7秒前
9秒前
大佬完成签到,获得积分10
9秒前
9秒前
隐形曼青的应助被坚定的采波采纳,获得10
10秒前
zfy157619完成签到,获得积分10
10秒前
10秒前
linhhhh完成签到,获得积分10
11秒前
李健的小迷弟的应助被冉小维采纳,获得10
11秒前
12秒前
12秒前
李慧敏完成签到,获得积分10
13秒前
zhang完成签到,获得积分10
13秒前
Jenson发布了新的文献求助10
13秒前
禾木呈完成签到,获得积分20
14秒前
LT完成签到 ,获得积分10
14秒前
14秒前
ChoHing完成签到,获得积分10
14秒前
一期一会发布了新的文献求助10
15秒前
16秒前
16秒前
领导范儿的应助被浮云客采纳,获得10
17秒前
脑洞疼的应助被美好小甜瓜采纳,获得10
18秒前
19秒前
20秒前
20秒前
danny完成签到,获得积分10
20秒前
21秒前
SciGPT的应助被ct采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500